• Publications
  • Influence
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
TLDR
This document reflects a process whereby a group of experts and opinion leaders revisited the 1992 sepsis guidelines and found that apart from expanding the list of signs and symptoms of sepsi to reflect clinical bedside experience, no evidence exists to support a change to the definitions. Expand
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
TLDR
A hypothetical model for staging sepsis is presented, which, in the future, may better characterize the syndrome on the basis of predisposing factors and premorbid conditions, the nature of the underlying infection, the characteristics of the host response, and the extent of the resultant organ dysfunction. Expand
The CRIT Study: Anemia and blood transfusion in the critically ill—Current clinical practice in the United States*
TLDR
The number of RBC transfusions a patient received during the study was independently associated with longer ICU and hospital lengths of stay and an increase in mortality and a nadir hemoglobin level of <9 g/dL was a predictor of increased mortality and length of stay. Expand
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion
TLDR
It is demonstrated that HMGB1 is an early mediator of injury and inflammation in liver I/R and implicates TLR4 as one of the receptors that is involved in the process. Expand
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
TLDR
Observations demonstrate that specific inhibition of endogenous HMGB1 therapeutically reverses lethality of established sepsis indicating thatHMGB1 inhibitors can be administered in a clinically relevant time frame. Expand
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
TLDR
It is reported that EP attenuates lethal systemic inflammation caused by either endotoxemia or sepsis even if treatment begins after the early tumor necrosis factor response, and a new strategy to pharmacologically inhibit HMGB1 release with a small molecule that is effective at clinically achievable concentrations is described. Expand
Laboratory models of sepsis and septic shock.
TLDR
There is a need for an animal model of severe chronic sepsis characterized by these features: persistent hypermetabolism, low systemic vascular resistance, respiratory failure severe enough to require mechanical ventilation, late (nonpulmonary) organ system failure, and death. Expand
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
TLDR
HA-1A is safe and effective for the treatment of patients with sepsis and gram-negative bacteremia and analyses that stratified according to the severity of illness at entry showed improved survival with HA- 1A treatment in both severely ill and less severely ill patients. Expand
Bench-to-bedside review: Cytopathic hypoxia
  • M. Fink
  • Medicine
  • Critical care
  • 12 September 2002
TLDR
Data is obtained to suggest that the most important mechanism underlying the development of cytopathic hypoxia is depletion of cellular stores of nicotinamide adenine dinucleotide (NAD+/NADH) as a result of activation of the enzyme, poly(ADP-ribose) polymerase-1. Expand
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
TLDR
In critically ill patients, weekly administration of a weekly dosing schedule of recombinant human erythropoietin (rHuEPO) reduces allogeneic RBC transfusion and increases hemoglobin. Expand
...
1
2
3
4
5
...